A multicenter phase II study of S-1 combined with irinotecan (CPT-11) for patients with advanced/recurrent breast cancer.
U. Toh
No relevant relationships to disclose
N. Iwakuma
No relevant relationships to disclose
H. Otsuka
No relevant relationships to disclose
M. Takenaka
No relevant relationships to disclose
E. Ogo
No relevant relationships to disclose
T. Fujii
No relevant relationships to disclose
M. Tanaka
No relevant relationships to disclose
K. Shirouzu
No relevant relationships to disclose